BRPI0507325A - antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia - Google Patents
antagonistas dos receptores nk-1 para melhorar a recuperação da anestesiaInfo
- Publication number
- BRPI0507325A BRPI0507325A BRPI0507325-1A BRPI0507325A BRPI0507325A BR PI0507325 A BRPI0507325 A BR PI0507325A BR PI0507325 A BRPI0507325 A BR PI0507325A BR PI0507325 A BRPI0507325 A BR PI0507325A
- Authority
- BR
- Brazil
- Prior art keywords
- anesthesia
- receptor antagonists
- improve recovery
- recovery
- improve
- Prior art date
Links
- 206010002091 Anaesthesia Diseases 0.000 title abstract 3
- 230000037005 anaesthesia Effects 0.000 title abstract 3
- 238000011084 recovery Methods 0.000 title abstract 3
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title abstract 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Toxicology (AREA)
- Surgery (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54069704P | 2004-01-30 | 2004-01-30 | |
| PCT/IB2005/000010 WO2005082366A1 (en) | 2004-01-30 | 2005-01-06 | Nk-1 receptor antagonists anesthesia recovery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0507325A true BRPI0507325A (pt) | 2007-07-03 |
Family
ID=34910695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0507325-1A BRPI0507325A (pt) | 2004-01-30 | 2005-01-06 | antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070155782A1 (enExample) |
| EP (1) | EP1713479A1 (enExample) |
| JP (1) | JP2007519701A (enExample) |
| KR (1) | KR100880391B1 (enExample) |
| CN (1) | CN1913893A (enExample) |
| AU (1) | AU2005216706B2 (enExample) |
| BR (1) | BRPI0507325A (enExample) |
| CA (1) | CA2554823A1 (enExample) |
| IL (1) | IL176830A0 (enExample) |
| MX (1) | MXPA06007964A (enExample) |
| NO (1) | NO20062965L (enExample) |
| RU (1) | RU2337685C2 (enExample) |
| WO (1) | WO2005082366A1 (enExample) |
| ZA (1) | ZA200605149B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1713504T1 (sl) | 2004-01-30 | 2017-10-30 | Zoetis Services Llc | Protimikrobni konzervansi za dosego večodmerne formulacije z uporabo beta-ciklodekstrinov za tekoče odmerne oblike |
| US9446029B2 (en) | 2010-07-27 | 2016-09-20 | Colorado State University Research Foundation | Use of NK-1 receptor antagonists in management of visceral pain |
| RU2489765C1 (ru) * | 2012-01-10 | 2013-08-10 | Открытое акционерное общество "Научно-исследовательский институт газоразрядных приборов "Плазма" (ОАО "Плазма") | Способ изготовления газонаполненного разрядника |
| CN114984223B (zh) * | 2022-05-31 | 2023-06-20 | 中国人民解放军陆军军医大学第二附属医院 | 生长激素促分泌素受体拮抗剂在制备吸入麻醉复苏制剂中的应用 |
| AT527172A1 (de) * | 2023-04-25 | 2024-11-15 | Vetviva Richter Gmbh | Maropitantformulierung |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US540897A (en) | 1895-06-11 | Harold f | ||
| US540644A (en) | 1895-06-11 | del yalle | ||
| SK278788B6 (sk) | 1991-05-31 | 1998-02-04 | Pfizer Inc. | Chinuklidínové deriváty, spôsob ich prípravy a pou |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| US6255320B1 (en) * | 1999-06-01 | 2001-07-03 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
| WO2003009848A1 (en) * | 2001-07-20 | 2003-02-06 | Pfizer Products Inc. | Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses |
-
2005
- 2005-01-06 CN CNA2005800036680A patent/CN1913893A/zh active Pending
- 2005-01-06 BR BRPI0507325-1A patent/BRPI0507325A/pt not_active IP Right Cessation
- 2005-01-06 KR KR1020067015267A patent/KR100880391B1/ko not_active Expired - Fee Related
- 2005-01-06 EP EP05702181A patent/EP1713479A1/en not_active Withdrawn
- 2005-01-06 RU RU2006126828/15A patent/RU2337685C2/ru not_active IP Right Cessation
- 2005-01-06 CA CA002554823A patent/CA2554823A1/en not_active Abandoned
- 2005-01-06 JP JP2006550323A patent/JP2007519701A/ja not_active Withdrawn
- 2005-01-06 AU AU2005216706A patent/AU2005216706B2/en not_active Ceased
- 2005-01-06 WO PCT/IB2005/000010 patent/WO2005082366A1/en not_active Ceased
- 2005-01-06 MX MXPA06007964A patent/MXPA06007964A/es not_active Application Discontinuation
- 2005-01-06 US US10/587,590 patent/US20070155782A1/en not_active Abandoned
-
2006
- 2006-06-22 ZA ZA200605149A patent/ZA200605149B/en unknown
- 2006-06-26 NO NO20062965A patent/NO20062965L/no not_active Application Discontinuation
- 2006-07-13 IL IL176830A patent/IL176830A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200605149B (en) | 2007-11-28 |
| MXPA06007964A (es) | 2007-01-26 |
| WO2005082366A1 (en) | 2005-09-09 |
| US20070155782A1 (en) | 2007-07-05 |
| KR20060127934A (ko) | 2006-12-13 |
| WO2005082366A8 (en) | 2005-12-15 |
| RU2006126828A (ru) | 2008-03-10 |
| IL176830A0 (en) | 2006-10-31 |
| NO20062965L (no) | 2006-07-21 |
| RU2337685C2 (ru) | 2008-11-10 |
| CN1913893A (zh) | 2007-02-14 |
| AU2005216706A1 (en) | 2005-09-09 |
| AU2005216706B2 (en) | 2007-11-29 |
| CA2554823A1 (en) | 2005-09-09 |
| JP2007519701A (ja) | 2007-07-19 |
| KR100880391B1 (ko) | 2009-01-30 |
| EP1713479A1 (en) | 2006-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0512985A (pt) | derivados de 3-carbamoil-2-piridona | |
| BRPI0417820A (pt) | heterociclos azabicìclicos como moduladores de receptor canabinóide | |
| BRPI0407097A (pt) | Antagonista do casr | |
| MA31593B1 (fr) | Derives de 2-aza-bicyclo[3.3.0]octane | |
| BRPI0415449A (pt) | combinações de compostos ativos fungicidas sinergìsticos | |
| GT200400277A (es) | Procedimiento de preparacion | |
| BR0013251A (pt) | Derivado de isoxazolina e herbicida que contém o mesmo como ingrediente ativo | |
| BRPI0407976A (pt) | tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6 | |
| MA31988B1 (fr) | Derives d'aminopyrazole | |
| HRP20010514B1 (en) | Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament | |
| EP1438973A4 (en) | MEANS FOR THE TREATMENT OF STRESS-RELATED DISEASES WITH MITOCHONDRIENE BENZODIAZEPINE RECEPTOR ANTAGONISTS | |
| SE0302760D0 (sv) | New compounds | |
| WO2006037047A3 (en) | The r-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents | |
| BR0213464A (pt) | Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide | |
| BR0214224A (pt) | Derivado de 4,4-diflúor-1,2,3,4-tetrahidro-5h-1-benzazepina ou sal do mesmo | |
| NO20013684L (no) | Substituerte fenetylaminderivater | |
| BR0102252A (pt) | Preparação de formulações de antogonistas dos receptores at1 usando as ciclodextrinas, seus derivados e os polìmeros biodegradáveis para o tratamento de hipertensão arterial, outras doenças cardiovasculares e suas complicações em animais de sangue quente | |
| NO20013060D0 (no) | Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff | |
| BR0317487A (pt) | O r-isÈmero de compostos de aminoácido beta como derivados de antagonistas de receptores de integrina | |
| WO2004110344A3 (en) | New azetidine compounds | |
| WO2007044796A3 (en) | Pyridazinone compounds as calcilytics | |
| DE60324685D1 (de) | 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren | |
| BRPI0507325A (pt) | antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia | |
| BRPI0511778A (pt) | derivados da naftalina úteis como ligantes do receptor 3 da histamina | |
| BRPI0517740A (pt) | compostos n-sulfonilaminobenzil-2fenóxi acetamida substituìda |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011. |